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glomerular filtration rate (eGFR) (mL/min) was calculated by Cockcroft-Gault (CG),
the mean bivalirudin dose achieving a therapeutic aPTT (50-80 seconds) was 0.07 ±
0.04, 0.15 ± 0.08, and 0.16 ± 0.07 for patients with an eGFR between 15-30, 31-60,
and >60, respectively (P=NS for 31-60 vs. >60; P<0.001 for 15-30 vs. 31-60). When
eGFR (mL/min/1.73 m2) was calculated by the Modification of Diet in Renal Disease
(MDRD) formula, the mean dose acheiving a therapeutic aPTT was 0.07 ± 0.04, 0.12
± 0.07, and 0.20 ± 0.07 for patients with eGFR between 15-30, 31-60, >60, respectively
(P<0.001 for 31-60 vs. >60 and 15-30 vs. 31-60; figure). No differences in adverse
clinical outcomes were observed.
Conclusion: Patients with suspected HIT receiving prolonged bivalirudin in the setting
of renal dysfunction can be treated safely and effectively following dose adjustments
in those with MDRD-determined moderate and severe renal impairment.
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Background: Bleeding complicating acute coronary syndrome (ACS) invasive care
is associated with increased ischemic events and mortality. Current anticoagulants are
limited by unpredictable pharmacodynamics and lack of specific reversibility. We
evaluated the effects of the REG1 System, an RNA aptamer, direct factor IXa inhibitor,
pegnivacogin, and its active control agent, animaversen, on access and non-access site
bleeding.
Methods: RADAR was a phase 2 trial evaluating the safety and efficacy of
anticoagulation with REG1 in non-ST-elevation ACS and planned early catheterization
via femoral access. A total of 640 patients were randomized 2:1:1:2:2 to pegnivacogin
with 25%, 50%, 75%, or 100% reversal with anivamersen with sheath removal at 10
minutes, or to heparin with sheath removal per standard care. Access and non-access
site bleeding at 30 days was assessed (ACUITY scale).
Results: Overall bleeding rates were similar across groups, with a trend toward less
major bleeding with more complete pegnivacogin reversal. Bleeding severity and
locations are shown (Table). The 25% reversal arm was terminated early due to excess
bleeding. One patient in the heparin arm had an intracranial bleed. Most bleeding
occurred ≤48 hours of randomization (81.1% with REG1 vs. 80% with heparin).
Conclusion: In non-ST ACS patients undergoing early invasive management, major
bleeding occurs in 10% of cases and is most often related to the vascular access site.
The REG1 System, with ≥ 50% reversal and early sheath removal resulted in similar
rates and severity of bleeding compared with heparin and standard sheath removal.
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Background: The EUROVISION Registry was designed to capture patterns of use
and short term outcomes associated with the use of bivalirudin (BIV) during PCI
procedures in Europe.
Methods: A total of 2018 consecutive BIV-treated patients (75% male, mean age 65.5
years) were included from 58 sites in 5 countries (Germany, Italy, France, Austria,
United Kingdom). In-hospital and 30-day outcomes were collected and included:
Death, MI, stroke, revascularization, major and minor bleeding, stent thrombosis and
thrombocytopenia.
Results: Indication for PCI included STEMI (34%), NSTEMI (25%), unstable angina
(16%) and stable angina (26%) with a median procedural duration of 28 minutes.
Overall, P2Y12 inhibitor preloading occurred in 95% of patients (91% clopidogrel
{65% with 600 mg and 33% with 300mg}, 9% prasugrel), 45% of patients received
other antithrombin therapy prior to PCI and were then switched to BIV, while
procedural glycoprotein inhibitor (GPI) use was low at 4.2%. Activated clotting time
was checked in only 2.8% suggesting operator familiarity with BIV predictable mode
of action and treatment effect. Among STEMI patients, 62% received a post-procedural
BIV infusion for a median duration of 122 minutes. Safety measures included major
bleeding (1.6%), stroke (5/2018, 0.2%), thrombocytopenia (0/2018), and stent
thrombosis (6/2018, 0.3%). Overall mortality was 1.0%, myocardiaI infarction rate
was 1.1% and urgent revascularization was 0.8%.
Conclusion: Adaptation of BIV as the foundation for all-comer PCI (including high
percentage of STEMI and NSTEMI patients) is associated with excellent ischemic
protection and unsurpassed safety. The rates observed in EUROVISION compare
favorably to other large existing registry datasets.
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Background: REG1 consists of pegnivacogin, an RNA aptamer factor IX inhibitor,
and its active controlling agent, anivamersen. RADAR assessed the safety and efficacy
of REG1 in patients with acute coronary syndromes (ACS) undergoing catheterization
via femoral access. REG1’s safety and efficacy in patients undergoing PCI has not
been described.
Methods: Patients were randomized in a 2:1:1:2:2 fashion to REG1 with 25%, 50%,
75% or 100% reversal, or heparin. The primary safety and efficacy endpoints were a
composite of major and minor ACUITY bleeding and the composite of death,
myocardial infarction, urgent target vessel revascularization (TVR), or recurrent
ischemia through 30 days.
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